When will Pfizer report Q1 2026 earnings?

Pfizer is expected to report Q1 2026 results next week, though the exact date has not been confirmed.

What are Pfizer's revenue expectations for Q1 2026?

Analysts expect Pfizer's revenue to be around $14.5 billion, down 18.5% from Q1 2025.

Why are Pfizer's earnings expected to decline?

The expected decline is mainly due to falling sales of its COVID-19 vaccine and Paxlovid, along with a lack of new products to offset the decline.

How could the earnings report affect Pfizer's stock?

Pfizer's stock is near its 52-week low; a negative surprise could add pressure, while positive results might trigger a temporary rebound.

Pfizer Q1 2026 Earnings Preview: Decline Expected

Pfizer (PFE) is expected to report lower earnings for Q1 2026 compared to last year. The company lacks the key ingredients for an earnings beat, with analysts forecasting a decline in both revenue and EPS.

Pfizer (PFE) is scheduled to report its first-quarter 2026 results next week, with Wall Street expecting a decline in both revenue and earnings compared to the same period last year. According to analysts, the company lacks the right combination of factors to deliver an earnings beat.

Key Financial Metrics

Metric	Q1 2026 (Est.)	Q1 2025 (Actual)	Change
Revenue	$14.5B	$17.8B	-18.5%
EPS	$0.48	$0.82	-41.5%

Highlights from the Report

No official statement has been released yet, but analysts attribute the expected decline to falling sales of COVID-19 vaccine and Paxlovid. The lack of strong new products also hampers growth.

Future Guidance

The company has not provided official guidance for the next quarter. It is expected to share its outlook during the earnings call.

Impact on the Stock

Pfizer (PFE) shares are trading near their 52-week low. Any negative surprise could add further pressure, while better-than-expected results might trigger a temporary rebound.

What This Means for Investors

Investors should closely monitor the earnings call for clues on the company's strategy to offset declining COVID revenues. Focus on the pipeline of new drugs and potential acquisitions will be key to assessing future growth prospects.